Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abcellera Biologics Inc
(NQ:
ABCL
)
2.730
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abcellera Biologics Inc
< Previous
1
2
3
4
Next >
AbCellera to Present at Upcoming Investor Conferences in November 2024
October 22, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
October 04, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
September 26, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at Upcoming Investor Conferences in September
August 29, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q2 2024 Business Results
August 06, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
July 31, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
June 25, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
May 28, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q1 2024 Business Results
May 07, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
May 01, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
April 08, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
April 03, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
March 19, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
March 11, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
March 05, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Resignation of Board Member
February 23, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at Upcoming Investor Conferences in March
February 22, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Full Year 2023 Business Results
February 20, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
January 23, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
December 20, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
November 16, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
November 03, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q3 2023 Business Results
November 02, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader
From
Prelude Therapeutics, Inc.; AbCellera
Via
GlobeNewswire
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
October 31, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
October 11, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
September 27, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
September 20, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
